Page 16 of 448: studies 151 to 160 of 4,475, newest first. Back to the ketamine overview
Molecular Neurobiology July 28, 2026
Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.
Journal of Clinical Psychopharmacology July 28, 2026
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
Molecular Psychiatry July 28, 2026
Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.
npj Mental Health Research July 27, 2026 Jennifer Swainson, P. Grewal, S. Polard et al.
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with...
IBRO Neuroscience Reports July 26, 2026 Jingwen Yang, Ting Huang, Meng Wang et al.
Background Deeper understanding of ketamine’s mechanism of action would contribute to the discovery of novel therapeutic targets with fast-onset actions. To gain insight on the mechanism underlying the antidepressant-like effects of ketamine, we focused on perineuronal nets (PNNs), an extracellular matrix structure that surrounds fast-spiking parvalbumin-positive interneurons and regulates...
McMaster University Medical Journal July 26, 2026 Annie Xiong, Sebastian Kolde, Paul S. Links
Background: Pharmacologic treatment options for borderline personality disorder (BPD) remain limited, and no medication has received regulatory approval for its treatment. Given the high rates of comorbid depression and suicidal ideation in BPD, there is growing interest in novel therapeutic approaches. Ketamine has been approved for treatment-resistant depression and acute suicidality, raising...
Cell Reports July 24, 2026 Viktor J Oláh, Isabelle F Witteveen, Tue G Banke et al.
GABAergic inhibitory interneurons balance brain activity by suppressing excessive excitatory signaling and shaping network oscillations. Despite this critical function, our understanding of how neural circuits regulate GABAergic systems remains limited. Although N-methyl-D-aspartate receptor (NMDAR) functionality is defined by the GluN2A-D subunits, the interneuron NMDAR subunit composition...
IBRO Neuroscience Reports July 24, 2026 Anahita Bahrami, Batool Ghorbani Yekta, Anita Baghdasarians
Schizophrenia is a severe neuropsychiatric disorder characterized by positive, negative, cognitive, mood-related, and motor symptoms. Sub-chronic ketamine administration is widely used to induce schizophrenia-like behavioral and cognitive alterations in rodents. Chlorogenic acid (CGA) is an abundant dietary phenolic acid with reported anti-inflammatory, antioxidative, and neuroprotective...
ACS Omega July 24, 2026
Comparative Electrocorticographic Signatures of S‑Ketamine and Racemic Ketamine in the Rat Visual Cortex Across Temporal Phases.
Comp Biochem Physiol C Toxicol Pharmacol July 23, 2026
A ketamine/methionine exposure paradigm, alone or combined with Lactobacillus rhamnosus GG, assessing schizophrenia-relevant behavioral, oxidative stress, and molecular endpoints in adult zebrafish.